Keynote 2 I Dr Silviu Itescu, Chief Executive Officer and Managing Director, Mesoblast Limited Building a global biotech from Australia

Transcription

1 Wednesday 25 October 8:30am 9:00am Conference Registration and BioIndustry Exhibition Hall open 9:00am 9:20am Official Opening & Welcome to AusBiotech :20am 9:50am 9:50am 10:30am 10:30am 11:00am Keynote 1 I Pfizer speaker to be confirmed Keynote 2 I Dr Silviu Itescu, Chief Executive Officer and Managing Director, Mesoblast Limited Building a global biotech from Australia Morning Tea & Networking with Exhibitors 11:00am 12:30pm Concurrent Stream 1 Concurrent Stream 2 Regenerative Medicine 1 Medical Countermeasures Dr Felicia Pradera, Program Leader, Medical Countermeasures, DMTC Ltd Dr Leigh Farrell, VP Corporate Strategy & Business Development, Certara Australian innovation policy and biotechnology Dr Hank Sciberras, Partner, Global Investment and Innovation Incentives (Gi³), Co. Director, Deloitte Tax Services A strategic view of the regenerative medicine landscape: with the first cellular therapy products being approved, what is still needed to make them readily available to patients Chair: Dr Silviu Itescu, Chief Executive Officer and Managing Director, Mesoblast Limited Dominic Wall, Chief Scientific Officer, Cell Therapies Pty Ltd Manufacturing and supply: scaling cellular therapies up and out for commercial supply AusBiotech 2017 Program - at 18 July

2 12:30pm 1:30pm AusBiotech Annual General Meeting (AusBiotech members only) 12:30pm 1:30pm Lunch & Networking with Exhibitors 1:30pm 3:00pm Concurrent Stream 3 Concurrent Stream 4 Regenerative Medicine 2 Complementary Medicine/Health Global IP session Asian Regenerative Medicine opportunities and perspectives Chair: to be confirmed Justin Howden, Head of Government Relations, Public Policy, Scientific Development and Community Engagement, Swisse Wellness Overview of the complementary medicines industry/sector Chair: Dr Lisa A. Haile, Partner and CoChair, Global Life Sciences Sector, DLA Piper, United States Ms Lyndall Soper, Assistant Secretary of the Complementary and Over the Counter Medicines Branch, TGA Complementary medicine current legislation and potential reform Professor Lynne Cobiac, Deputy Director & Science Director, CSIRO Health and Biosecurity, CSIRO Precision health and wellness AusBiotech 2017 Program - at 18 July 2017 Speakers to be confirmed Chair: to be confirmed Korean spotlight Dr So Ra Park, Professor, Department of Physiology, Medical College of Inha Univ, Korea and Head of Global Stem Cell and Regenerative Medicine Acceleration Center (GSRAC) o Regulatory o Government support / reimbursement o Industry/Company profiles Japanese spotlight Dr Akihiko Iwai, Vice Deputy Chairman of Forum for Innovative Regenerative Medicine (FIRM) and Divisional Senior Vice President of Candidate Discovery Science Labs, Drug Discovery Research, Astellas Pharma Inc. o Regulatory o Government support / reimbursement o Industry/Company profiles 2

3 3:00pm 3:30pm 3:30pm 3:45pm 3:45pm 5:00pm 5:30pm 7:00pm Thursday 26 October 7:00am 8:30am 9:00am 5:00pm Afternoon Tea & Networking with Exhibitors Announcement of the AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2017 Plenary 1 l Update: Key issues facing big pharma globally Chair: Lorraine Chiroiu, Deputy Chief Executive Officer, AusBiotech Ltd Panel: Benjamin Thorner, Senior Vice President and Head of Business Development & Licensing, Merck Research Laboratories, UK Dr Kevin Lynch, Vice President Search & Evaluation, AbbVie, United States Dr Anand Gautam, Senior Director, Head of External Science & Innovation, Australia, New Zealand and Southeast Asia, Pfizer Australia Jessica Droge, Executive Director, Business Development, Amgen Inc, United States AusBiotech 2017 Welcome Reception BioIndustry Exhibiton Hall TechInSA Reception further details to be confirmed Adelaide Oval Bionomics-Merck Annual Symposium separate program to be advised Regenerative Medicine 3 What technologies are hot in regenerative medicine now and in the future? Chair: Dr Dianne Jackson Matthews, Director of Regulatory Affairs, ERA Consulting Professor Melissa Little, Program Leader, Stem Cells Australia Transitioning to the Future: Australia s stem cell future Dr Killian Kelly, Vice President Product Development, Cynata Therapeutics Next generation stem cells: ipsc potential AusBiotech 2017 Program - at 18 July

4 Riverbank Rooms 3 and 4, Adelaide Convention Centre 8:30am 5:00pm 9:00am 10:30am (40 min) (40 min) 10.30am 11.00am Conference Registration, BioIndustry Exhibition and AusPartnering Open Plenary Session 2 Professor Barry Marshall, Nobel Laureate & Dr Jenny Harry, Chief Executive Officer, Ondek Pty Ltd Plenary Session 3 Craig Rayner, President, d3 Medicine a Certara company Drug Development in Fast Forward: Lean, value-focused drug development strategies of the future Morning Tea and Networking with Exhibitors Concurrent Stream 5 Concurrent Stream 6 Clinical Trials 1 11:00am 12:30pm Session details to be confirmed Technologies to tackle emerging threats: Capitalising on Australia s capability and changing funding models to enhance commercialisation success Chair: Jennifer Hertz, Managing Director, Biointelect Pty Ltd Professor Seshandry Vasan, Senior Business Development Manager, Public Health England, UK (to be confirmed) Professor Jodie McVernon, Professor and Director of Doherty Epidemiology, Doherty Institute Clinical trials, including strategies to help Australia maintain its competitive advantage and continue to attract international R&D Chair: to be confirmed Jérôme Armellini, Head of Asia Therapeutic Strategy, Therapeutic Science & Strategy Asia Pacific, QuintilesIMS Using big data to make informeddecisions for clinical development strategy AusBiotech 2017 Program - at 18 July

5 12:30pm 1:30pm 1:30pm 3:00pm Lunch, Networking with BioIndustry Exhibitors Concurrent Stream 7 Concurrent Stream 8 Clinical Trials 2 Session title TBC Dr Caroline Popper, Co-Founder and President, Popper and Co., United States Cyber Risks Travis McIntosh, Custom Industry Solutions Manager, Australia & New Zealand Life Science Specialist, Asia Pacific, Chubb Insurance Australia Limited Australian Clinical Trials in the International Context Localising International Clinical Trials key findings about making them work in the Australian clinical setting Australian Regulations similarities, differences, and key points to remember about what needs to be done in Australia compared to other jurisdictions Hot topics in Ethical Research 3:00pm 3:30pm Afternoon Tea & Networking with BioIndustry Exhibitors 3:30pm 5:00pm (20 minutes) Plenary Session 4 Peter Molloy, Chief Executive Officer, Race Oncology Performance of the Australian biotech sector - with a focus on drug development companies Clinical Trials 3 Clinical Development Optimization- Data Driven Decision Making For Success AusBiotech 2017 Program - at 18 July

6 (60 minutes) Plenary Session 5 Global Investment update International investor speakers to be confirmed Session speakers to be confirmed AusBiotech 2017 Program - at 18 July

7 7:00pm 11:00pm Conference Dinner Friday 27 October 8:30am 1:00pm 9.00am 11.00am 9:00am 10:30am (40 min) Conference Registration, BioIndustry Exhibition & AusPartnering open BioIndustry Exhibition Hall Trade Morning Plenary Session 6 Millis Oration Dr C. Glenn Begley, Chief Executive Officer, Biocurate Pty Ltd (40 min) 10:30am 11:00am 11:00am 11:30am Plenary Session 7 Charlie Day, Chief Executive Officer, Office of Innovation and Science Australia Update on ISR System Review/2030 Strategic Plan Morning Tea and Networking with BioIndustry Exhibitors Plenary Session 8 Tim Oldham, Chief Executive Officer, Cell Therapies Inventing supply chains for 21 st century cures implications for product development AusBiotech 2017 Program - at 18 July

8 Concurrent Stream 11 Concurrent Stream 12 11:30am 1:00pm Getting into preclinical testing: Australia s development capabilities We now have money flowing into biotech/pharma through the R&D Tax incentive, angel investor tax breaks, the BTF. We have the acknowledgment that translation is key. So once you have the IP and an indication of your development path, where do you go to get advice and where are the capabilities for development and testing for your preclinical proof-of-concept and preclinical studies. What capabilities are available in Australia and what is needed? Chair: Julie Phillips, Chief Executive Officer, BioDiem Ltd Mal Eutick, Chief Executive Officer, Phebra Australia Richard Buchta, Formultyica Professor Sue Charman, Director of the Centre for Drug Candidate Optimisation Monash Institute of Pharmaceutical Sciences IDT representative to be confirmed Innovation For Commercialisation Successful commercialisation of a new product challenges the developer s depth and accuracy of their understanding about the intended customer and market. This knowledge is essential in moulding the product features and characteristics to best penetrate and compete in a global market before competitively communicating the product value to customers and securing successful sales. While the products developed in the biotech industry emanate from complex and sophisticated science and compete in an even more complex and multi-layered market structure, the principles behind successful commercialisation are just as valid. This panel will discuss the strategic, legal, investor and customer perspectives facing biotech product commercialisation in Australia today. Panel: Dr Rob Crombie, Commercialisation Adviser, Accelerating Commercialisation, Entrepreneurs' Programme Andrew Maxwell, Managing Director, Chatsworth Associates Rob McInnes, Partner, DibbsBarker Dr Ingmar Wahlqvist, Investment Manager, Brandon Capital Partners Michelle Burke 1:00pm 2:30pm AusBiotech 2017 Closing Celebration and hand over to AusBiotech 2018 BioIndustry Exhibition Hall AusBiotech 2017 Program - at 18 July

9 2:00pm 5:30pm One Ventures/TechinSA Making a Project Investable (invitation only) Skyway Rooms 1-3 AusBiotech 2017 Program - at 18 July